Evolva announces change in management team

Reinach, Switzerland, 2 June 2010 – Evolva Holding SA (SIX: EVE) today announced that Dr. Melya Hughes Crameri, CEO of Evolva’s US subsidiary Genetic Chemistry, has resigned from her role effective June 18th, in order to pursue other opportunities. Dr. Panchapagesa Murali, CEO of Evolva’s Indian subsidiary, will serve as acting CEO of Evolva’s US operations until a successor is named.

Neil Goldsmith, CEO and Managing Director of Evolva Holding SA commented, “ Melya has been an integral part of the management team over the past five years. On behalf of the Board and the Evolva team, we extend our gratitude to Melya for her contributions and wish her the best in her future endeavours. ”

Mr. Murali has over 20 years experience in pharmaceutical and healthcare R&D. He has led Evolva’s Indian operations since September 2006 and is a member of the Group Management Team of Evolva Holding SA.

-- ends --

Contact Details

Download PDF

• English

About Evolva Holding SA

Evolva's proprietary discovery technology platform uses a “disruptive” technological approach to the creation of novel small compounds that differs sharply from the prevailing synthetic chemistry and protein engineering approaches in the pharmaceutical industry today. Based on this technology, Evolva has a number of discovery and pre-clinical partnerships which in 2009 generated revenues of CHF 18.9 million. Evolva also has an attractive pipeline of compounds – one drug candidate (for renal and cardiovascular diseases) entered Phase I at the beginning of 2009, and two others (an anti-fungal and an anti-viral) are in late preclinical stages. Evolva is listed in the main standard of the SIX Swiss Exchange with the ticker EVE. For more information see www.evolva.com.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.